POST-TEST

Oncology Today with Dr Neil Love: Key Presentations from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2025 Congress — Acute Myeloid Leukemia Edition

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **What was the approximate complete response rate in the ASCERTAIN-V trial of the all-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed acute myeloid leukemia (AML) not eligible for intensive induction chemotherapy?**
   a. 17%
   b. 47%
   c. 87%

2. **The ongoing Phase II QuANTUM-Wild study is evaluating quizartinib with intensive chemotherapy for which patients with newly diagnosed AML?**
   a. Those with FLT3-TKD-negative AML
   b. Those with FLT3-ITD-negative AML
   c. Those with FLT3-TKD- and FLT3-ITD-negative AML

3. **Which of the following conditions is a treatment-related adverse event of special interest associated with menin inhibitors?**
   a. Ocular toxicity
   b. Differentiation syndrome
   c. Interstitial lung disease

4. **Olutasidenib has demonstrated activity in which category of AML?**
   a. FLT3-ITD mutant
   b. FLT3-TKD mutant
   c. IDH1-mutant

5. **The BEAT AML trial of triplet therapy with azacitidine/venetoclax/revumenib for newly diagnosed KMT2A-rearranged or NPM1-mutant AML demonstrated which finding?**
   a. The overall response rate (ORR) in the overall patient population was approximately 88%
   b. Patients with KMT2A-rearranged AML did not respond to the triplet regimen
   c. The ORR was higher for patients with NPM1-mutant AML than for those with KMT2A-rearranged AML